BKM120 for Patients With PI3K-activated Tumors

Inclusion Criteria

• •Patient had a confirmed diagnosis of a solid tumor or hematological malignancy with the exception of endometrial cancer, glioblastoma, nonsmall cell lung cancer, prostate cancer or breast cancer.
• •Patient's tumor was evaluated and pre-identified to have activation of the PI3K pathway, at a CLIA certified laboratory
• •Patient must have received at least one prior treatment for recurrent metastatic and /or locally advanced disease and for whom no standard therapy options was anticipated to result in a durable remission.
• •Patient must have had progressive and measurable disease as per RECIST 1.1. or other appropriate hematological guidelines
• •Patient had an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1